IMVp-16方案联合顺铂治疗难治性恶性淋巴瘤近期疗效分析(附22例报告)

ANALYSIS OF SHORT TERM RESPONSE IN REFRACTORY MALIGNANT LYMPHOMA TREATED WITH IMVp 16 REGIMEN AND CISPLATIN A REPORT OF 22 CASES

目的对我所１９９５年５月～１９９８年５月２２例难治性恶性淋巴瘤疗效分析。方法采用ＩＭＶｐ１６方案联合顺铂治疗难治性恶性淋巴瘤２２例。其中Ｂ细胞１４例，Ｔ细胞４例，霍奇金病４例。恶性程度均为中～高度，分期为Ⅱ～Ⅳ期。结果治疗结果ＣＲ９例，占４０９％。ＰＲ８例，占３６４％。有效率为７７３％。主要毒性为骨髓抑制，白细胞减少Ⅲ～Ⅳ度为４５５％。胃肠道反应率４０９％。结论ＩＭＶｐ１６方案联合ＤＤＰ化疗治疗难治性恶性淋巴瘤是较有效且安全的方案。

PURPOSE From May 1995 to May 1998,our institute has treated 22 patients of refractory malignant lymphoma using IMVp 16 regimen and cisplatin.METHODS Among the 22 patients,there were 14 cases of B cell lymphomas,4 cases of T cell lymphomas,4 cases of Hodgkin′s disease.Their degrees of malignancy were intermediate and high grade,and the patients were in stage Ⅱ～Ⅳ.RESULTS The results of the treatment show that 9 cases achieved CR(40.9%) and 9 cases achieved PR(36.4%).The response rate was 77.3%.Myelosuppression was the main dose limiting toxicity.GradeⅢ～Ⅳ leucopenia occured in 45.5%. Nausea and vomiting occured in 40.9%.CONCLUSION IMVp 16 regimen combinated DDP chemotherapy is aeffective and safety method for the patients of refractory malignant lymphoma.